Presenilin-dependent γ-secretase-mediated control of p53-associated cell death in Alzheimer's disease

被引:151
作者
da Costa, CA
Sunyach, C
Pardossi-Piquard, R
Sévalle, J
Vincent, B
Boyer, N
Kawarai, T
Girardot, N
George-Hyslop, PS
Checler, F
机构
[1] Univ Nicaragua, Inst Mol & Cellular Pharmacol, Coeduc Unit Res 6097, Team Fdn Med Res,Natl Ctr Sci Res,Natl Union Auto, F-06560 Valbonne, France
[2] Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Toronto, ON, Canada
[3] Univ Hlth Network, Toronto, ON, Canada
[4] Grp Hosp Pitie Salpetriere, Med Res Unit 289, F-75634 Paris, France
[5] Grp Hosp Pitie Salpetriere, Natl Inst Hlth, F-75634 Paris, France
关键词
presenilins; gamma-secretase; AICD; apoptosis; p53; Alzheimer's disease;
D O I
10.1523/JNEUROSCI.0651-06.2006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Presenilins ( PSs) are part of the gamma-secretase complex that produces the amyloid beta-peptide ( A beta) from its precursor [ beta-amyloid precursor protein ( beta APP)]. Mutations in PS that cause familial Alzheimer's disease ( FAD) increase A beta production and trigger p53-dependent cell death. We demonstrate that PS deficiency, catalytically inactive PS mutants, gamma-secretase inhibitors, and beta APP or amyloid precursor protein-like protein 2 ( APLP2) depletion all reduce the expression and activity of p53 and lower the transactivation of its promoter and mRNA expression. p53 expression also is diminished in the brains of PS- or beta APP-deficient mice. The gamma- and epsilon-secretase-derived amyloid intracellular C-terminal domain ( AICD) fragments ( AICDC59 and AICDC50, respectively) of beta APP trigger p53-dependent cell death and increase p53 activity and mRNA. Finally, PS1 mutations enhance p53 activity in human embryonic kidney 293 cells and p53 expression in FAD-affected brains. Thus our study shows that AICDs control p53 at a transcriptional level, in vitro and in vivo, and that FAD mutations increase p53 expression and activity in cells and human brains.
引用
收藏
页码:6377 / 6385
页数:9
相关论文
共 64 条
  • [41] Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and potentiate Aβ42 recovery from human cells
    Marambaud, P
    Ancolio, K
    Lopez-Perez, E
    Checler, F
    [J]. MOLECULAR MEDICINE, 1998, 4 (03) : 147 - 157
  • [42] MIYASHITA T, 1995, CELL, V80, P293
  • [43] Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje
  • [44] Neprilysin activity and expression are controlled by nicastrin
    Pardossi-Piquard, R
    Dunys, J
    Yu, G
    St George-Hyslop, P
    Alves da Costa, C
    Checler, F
    [J]. JOURNAL OF NEUROCHEMISTRY, 2006, 97 (04) : 1052 - 1056
  • [45] Presenilin-dependent transcriptional control of the Aβ-degrading enzyme neprilysin by intracellular domains of βAPP and APLP
    Pardossi-Piquard, R
    Petit, A
    Kawarai, T
    Sunyach, C
    da Costa, CA
    Vincent, B
    Ring, S
    D'Adamio, L
    Shen, J
    Müller, U
    Hyslop, PS
    Checler, F
    [J]. NEURON, 2005, 46 (04) : 541 - 554
  • [46] Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289
  • [47] Regulation of transcription of the human presenilin-1 gene by Ets transcription factors and the p53 protooncogene
    Pastorcic, M
    Das, HK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (45) : 34938 - 34945
  • [48] Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains
    Pérez, A
    Morelli, L
    Cresto, JC
    Castaño, EM
    [J]. NEUROCHEMICAL RESEARCH, 2000, 25 (02) : 247 - 255
  • [49] PerezTur J, 1995, NEUROREPORT, V7, P297
  • [50] Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression
    Roperch, JP
    Alvaro, V
    Prieur, S
    Tuynder, M
    Nemani, M
    Lethrosne, F
    Piouffre, L
    Gendron, MC
    Israeli, D
    Dausset, J
    Oren, M
    Amson, R
    Telerman, A
    [J]. NATURE MEDICINE, 1998, 4 (07) : 835 - 838